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Abstract 
Brain natriuretic peptide (BNP) modulates several biological processes by 
activating the natriuretic peptide receptor A (NPR-A). Atria and ventricles 
secrete BNP. BNP increases natriuresis, diuresis and vasodilatation, thus 
resulting in a decreased cardiac workload. 
BNP and NT-proBNP, which is the biologically inactive N-terminal portion of 
its pro-hormone, are fast and sensitive biomarkers for diagnosing heart 
failure. The plasma concentrations of both BNP and NT-proBNP also 
correlate with left ventricular function in patients with acute exacerbation of 
COPD, even without history of heart failure. Several studies have been 
conducted in vitro and in vivo, both in animals and in humans, in order to 
assess the potential role of the NPR-A activation as a novel therapeutic 
approach for treating obstructive pulmonary disorders. Unfortunately, these 
studies have yielded conflicting results.  
Nevertheless, further recent specific studies, performed in ex vivo models of 
asthma and COPD, have confirmed the bronchorelaxant effect of BNP and its 
protective role against bronchial hyperresponsiveness in human airways. 
These studies have also clarified the intimate mechanism of action of BNP, 
represented by an autocrine loop elicited by the activation of NPR-A, localized 
on bronchial epithelium, and the relaxant response of the surrounding ASM, 
that does not expresses NPR-A.  
Therefore, this review explores the teleological activities and paradoxical 
effects of BNP with regard of chronic obstructive respiratory disorders, and 
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provides an excursus on the main scientific findings that explain why BNP 
should be considered much more than a biomarker. 
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1. Background 
Natriuretic peptide (NP) hormones are small cardiovascular-derived peptides 
characterized by a 17 aminoacid ring and include atrial natriuretic peptide 
(ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) 
[1]. NPs are encoded by different genes, synthesized as prepropeptides and 
stored as high molecular mass propeptides (proANP, proBNP and proCNP). 
The cleavage of propeptide results in the formation of the daughter ANP, BNP 
and CNP, which are characterized by lower molecular mass [1].  
NPs modulate several biological effects by interacting with specific natriuretic 
peptide receptors (NPRs) including NPR-A, NPR-B and NPR-C, a family of 
homologous single-transmembrane, glycosylated receptors [2, 3]. The 
stimulation of NPR-A and NPR-B activates an intracellular particulate domain 
with guanylate cyclase (GC) activity that promotes the synthesis of cyclic 
guanosine monophosphate (cGMP) [4]. NPR-C does not modulate cGMP 
levels but inhibits adenylyl cyclase (AC) and activates phospholipase C (PLC), 
and removes NPs from the circulation. In fact NPR-C serves as a “clearance” 
receptor leading to internalization and lysosomal degradation of NPs [5, 6]. 
ANP and BNP are the biological ligands of NPR-A, whereas CNP 
preferentially binds to NPR-B. ANP and BNP both have a relatively high 
affinity for their respective receptor sub-types, although ANP is about 10 fold 
more potent than BNP [1, 7]. NPR-A is expressed in the cardiovascular 
system (cardiac atria and ventricles, aorta and peripheral vasculature), 
kidney, skin, platelets, and sympathetic fibers [1]. In both animals and man 
NPR-A has also been widely identified on a variety of pulmonary cells such as 
endothelial and smooth muscle cells of pulmonary blood vessels, type II 
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alveolar cells, and epithelial and airway smooth muscle cells in bronchi and 
bronchioles [8-12], whereas NPR-B is mainly expressed in veins as compared 
with arteries [7]. 
 
2. Cardiovascular and renal actions of NPs 
Under physiological conditions ANP is secreted from cardiac atria, BNP from 
both atria and ventricles, whereas CNP is mainly released primarily from 
nervous tissue and vascular endothelium [1]. However, in a number of 
cardiovascular disorders and conditions associated with elevated blood 
pressure or volume overload, increased gene expression of ANP may be 
detected in the left ventricle [13] in association with rapid and constant 
enhancement of BNP transcripts [14, 15].  
ANP and BNP have similar pharmacological profiles since they act on the 
same NP receptor and can induce natriuresis, vasodilatation and inhibition of 
aldosterone synthesis. Furthermore, these NPs have anti-mitogenic effects on 
endothelial and vascular smooth muscle cells [16]. In the central nervous 
system both ANP and BNP induce thirst suppression, inhibition of the release 
of antidiuretic and adrenocorticotropic hormones, as well as a reduction of 
sympathetic tone. Altogether these effects contribute to the hypotensive 
properties of NPs [16]. 
The action of CNP is different compared with that of ANP and BNP since it 
acts as an autocrine/paracrine mediator in blood vessels, through the 
modulation of vascular tone and cell growth [1, 16]. Thus, CNP is less 
effective at inducing diuresis and natriuresis compared with the other NPs but 
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is more effective at modulating the autonomic control of vascular tone [17, 
18]. 
These pharmacological properties of NPs underpin why they have been 
implicated in the pathogenesis of congestive heart failure, as proposed by 
Woodard and Rosado [19]. In fact ANP and BNP increase both natriuresis 
and diuresis and induce local vasodilatation in response to cardiac failure, 
whereas CNP modulates the cardiac remodeling and inhibits the proliferation 
of vascular smooth muscle cells (VSMCs) [19]. Taken together, these actions 
of NPs lead to a reduction in blood pressure and circulatory volume, resulting 
in a decreased cardiac workload [19]. 
 
3. BNP as a biomarker 
There is a large body of evidence that the levels of BNP and the biologically 
inactive N-terminal portion of its pro-hormone, NT-proBNP, correlate well with 
the severity of heart failure [20]. Since they function as an indicator of 
increased ventricular mass and a surrogate marker for heart failure, NT-
proBNP and BNP are regarded as biomarkers, namely biological parameters 
that are objectively measured and evaluated as indicators of normal biological 
processes, pathogenic processes or pharmacological responses to a 
therapeutic intervention [21]. 
NT-proBNP has a longer plasma half-life and exists at considerably higher 
concentrations compared with BNP [22]. It is significantly more stable at room 
temperate and current laboratory assays are highly sensitive and specific. 
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Furthermore, all commercially available NT-proBNP assays utilize the same 
set of antibodies, which greatly simplifies intra-laboratory comparisons. 
When used in conjunction with other clinical information, BNP and NT-proBNP 
levels are useful in establishing or ruling out the diagnosis of heart failure in 
patients with acute dyspnea [23]. For both BNP and NT-proBNP to exclude 
acute heart failure in symptomatic patients, very low values are necessary 
[24]. For BNP, the value is approximately 20 to 30 pg/mL, while for NT-
proBNP, a cut point that has a negative predictive value of 98% to 99% is 300 
pg/mL. Values above these levels, whether or not they are below the rule in 
cut point, may be associated with heart failure. However, the International 
Collaborative Of NT-proBNP (ICON) study [25] suggested that, for the 
exclusion of acute heart failure, a general age-independent cut-point of 300 
pg/ml should be used, whereas for diagnosis of heart failure, age-dependent 
cut-points are more useful: namely NT-proBNP >450 pg/ml for patients <50 
years; >900 pg/ml for patients in between 50 and 75 years; and NT-proBNP 
>1,800 for patients >75 years. 
Since the use of BNP and NT-proBNP for the diagnosis of heart failure has 
dramatically impacted the standard of care in this pathological condition, all 
major societies recommend the use of these biomarkers for the diagnosis of 
heart failure in their clinical practice guidelines [20, 26, 27]. BNP and NT-
proBNP concentrations typically fall with therapies proven to improve mortality 
in heart failure with decreased left ventricular ejection fraction [28-30]. BNP-
guided therapies decrease mortality and reduce cardiovascular events, 
although do not decrease overall hospitalizations. 
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Adding routine BNP testing in patients with a history of asthma or chronic 
obstructive pulmonary disease (COPD) increases the detection of newly 
diagnosed or previously unrecognized chronic heart failure by approximately 
20% [31]. In any case, BNP levels are elevated in patients with pulmonary 
diseases, at least in those with concomitant right ventricular (RV) dysfunction 
and pulmonary arterial hypertension [32], although BNP levels are 
significantly lower in right heart failure due to COPD compared with right heart 
failure due to left ventricular systolic heart failure [33]. 
Elevated BNP concentrations identify significant pulmonary hypertension with 
a sensitivity of 0.85 and specificity of 0.88 and predicted mortality [34]. It has 
been shown that plasma BNP levels may be elevated in patients with COPD 
and correlate not only with pulmonary arterial pressure but also with forced 
vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and partial arterial 
oxygen pressure [35]. However, there is contrasting documentation indicating 
that plasma BNP levels are also elevated in patients with stable COPD 
without pulmonary hypertension or cor pulmonale [36]. In these patients, there 
is no significant correlation between plasma BNP level and pulmonary 
function or hypoxia, but there is a significant correlation between plasma BNP 
level and % ejection fraction and pulmonary artery systolic pressure. 
Intriguingly, they are also increased in patients with COPD with normal right 
ventricular function after exercise [37]. 
Several studies have highlighted the importance of the BNP dosage in 
detecting left ventricular dysfunction in patients with acute exacerbation of 
COPD (AECOPD), even without history of heart failure [38-40], although 
echocardiographic examinations are able to document cardiac systolic and 
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diastolic dysfunction in only a small number of patients during the AECOPD 
[41]. Whatever the case may be, the period until initial AECOPD in subjects 
with high plasma BNP level seems to be significantly shorter [36]. 
Furthermore, in patients with AECOPD, BNP levels independently predict the 
need for intensive care [42], and elevated levels of NT-proBNP are strong 
predictors of early mortality among patients admitted to hospital with acute 
exacerbations of COPD independently of other known prognostic indicators 
[43]. There may be a link between an elevated level of BNP or NT-proBNP 
and increased cardiovascular mortality in AECOPD, although the data 
currently available are not conclusive [44]. 
 
4. NPs and airway smooth muscle cell 
Several studies have revealed that airway smooth muscle (ASM) cells 
obtained from subjects with asthma display mechanical and phenotypical 
differences from that of ASM obtained from non-asthmatic subjects.  ASM 
cells obtained from subjects with asthma showed a marked increase in force 
generation, capacity of shortening, degree of shortening and sensitivity to 
agonists [45, 46]. Moreover, hypertrophy of ASM in patients with severe 
asthma has been associated with a 5-fold greater positivity for markers of 
proliferating than ASM obtained from healthy subjects [47]. However, other 
studies failed to document mechanical differences between ASM derived from 
asthmatic and non-asthmatic donors [48, 49]. An increased amount of 
expression of contractile cytoskeletal proteins that characterizes the 
contractile phenotype have also been described [50], as have phenotypic 
differences in the sensitivity to proliferative and apoptotic stimuli for ASM [51]. 
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Studies on the expression of components of the contractile cytoskeletal have 
also been observed in ASM obtained by endobronchial biopsy from subjects 
with asthma, demonstrated as an increased mRNA expression of myocitic 
markers, including myosin light chain kinase and total smooth muscle myosin 
heavy chain, when compared to ASM obtained from non-asthmatic donors 
[52, 53]. The increased expression of specific smooth muscle markers has 
been linked to increased bronchial smooth muscle mass and ASM cell 
functional differences observed in asthmatic patients [54]. Most of the 
information concerning the effects of BNP on ASM cell proliferation has been 
obtained from in vitro models. For example, BNP inhibited angiotensin II-
induced smooth muscle cell proliferation, likely mediated by a decreased 
calcium influx, reduced ROS production and Akt signal transduction [55]. 
 
5. Expression of NPRs in human bronchi 
RT- and qRT-PCR both documented that human bronchial tissue expresses 
significant levels of NPR-A transcripts, whereas the gene expression of NPR-
B and NPR-C were scarce or even not detectable [8]. As evidenced by 
immunohistochemistry, NPR-A was localized at the level of bronchial 
epithelium and inflammatory cells of lamina propria, whereas NPR-A was 
barely detected in ASM and absent on the surface of goblet cells [8]. NPR-A 
transcripts were also detected on BEAS-2B cells, an immortalized human 
bronchial epithelial cell line that has been widely used to study the effect of 
BNP on human bronchi and ASM [8, 56, 57]. 
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Neither the passive sensitization of human bronchi, an ex vivo model that 
closely mimics important characteristics of BHR in asthmatic patients [8, 56, 
58-60], did not modify the NPR-A gene expression [8], nor the stimulation with 
methacholine or histamine altered the NPR-A levels [8]. NPR-A transcripts 
were increased after BNP treatment in both non-sensitized and passively 
sensitized bronchi, whereas the selective antagonism of M2 muscarinic 
receptors by methoctramine prevented the receptor over-expression, 
suggesting that antagonizing M2 muscarinic receptors may act as a negative 
feedback loop in the NPR-A transcriptional pathway [8].  
 
6. NPR-A activation and airways: past and recent knowledge  
NPR-A is expressed in the airways of several animal species [9-11] and 
administration of exogenous ANP induced relaxation of ASM of rats, guinea 
pigs and cows in vitro [61-63]. Unfortunately, only a few studies have 
investigated the ability of ANP to induce relaxation of human ASM in vitro, and 
the limited data available in the literature have proposed conflicting 
conclusions, with some studies documenting weak relaxation [64] and others 
showing no significant relaxant effect [65]. In any case, ANP seemed to have 
a protective effect on propranolol-induced bronchoconstriction in allergic 
guinea pigs in vivo [66]. ANP reduce airway resistance in normal subjects 
[67]. Further studies have demonstrated that ANP may induce bronchodilation 
and prevent bronchial hyperresponsiveness (BHR) in asthmatic patients when 
given intravenously or by inhalation, and have also demonstrated the ability of 
ANP to modify the bronchoconstriction in response to inhaled histamine or 
nebulized water in man [68-74]. 
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Studies carried out in laboratory animals have also demonstrated that BNP 
may relax tracheal smooth muscle in vitro and prevent ovalbumin-induced 
bronchoconstriction and microvascular leakage in vivo [75, 76]. Nevertheless, 
until some years ago specific research on the ability of BNP to relax human 
ASM were still lacking in the literature. However, it has been documented that 
the administration of nesiritide, a human recombinant BNP, induces 
bronchodilation in patients with asthma and that PL-3994, a novel NPR-A 
agonist resistant to neutral endopeptidase, relaxes the tone of human 
precision-cut lung slices (PCLS) pre-contracted with carbachol [77, 78]. 
Combined, these evidences (Table 1) would suggest that the activation of 
NPR-A might modulate bronchial tone in patients suffering from chronic 
obstructive pulmonary disorders. 
 
7. Influence of BNP on the contractile tone of human ASM: current 
knowledge 
BNP was ineffective at relaxing medium isolated human bronchi pre-
contracted with carbachol, and produced a weak relaxant response of 
passively sensitized airways pre-contracted with histamine (≃60% vs. 
maximal relaxation induced by papaverine) [58]. This modest effectiveness of 
BNP may be correlated with the absence of NPR-A at the level of ASM. 
Moreover, the modest effect of BNP on isolated human bronchi [58] is in 
contrast with the ability of nesiritide to produce considerable bronchodilation in 
patients with asthma [78]. This discrepancy may be explained by the fact that 
BNP probably does not act as a direct bronchodilator on ASM [56]. It has also 
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been suggested that the ability of BNP to improve lung function in vivo may be 
related to other effects, such as the reduction of airway microvascular leakage 
and plasma exudation into the airway [79, 80]. 
The bronchodilator effect of BNP has also been investigated in human small 
airways by using PCLS preparations and it has been compared with the effect 
elicited by PL-3994 [77]. In contrast to what has been observed in human 
isolated human bronchi [58], BNP was able to induce a relaxant response of 
bronchioles pre-contracted with carbachol (≃50% vs. maximal relaxation 
induced by salbutamol) [77]. Furthermore, although PL-3994 induced a potent 
and concentration-dependent relaxation of PCLS preparations, its 
effectiveness was modest (≃30% vs. maximal relaxation induced by 
salbutamol) and was less effective when compared with BNP [77]. 
Further studies have investigated why BNP appears to be more effective as a 
bronchoprotective agent than as a direct bronchodilator. Thus, recent studies 
have demonstrated that BNP shifts rightward the contraction-response curve 
induced by histamine in passively sensitized bronchi (potency reduced by ≃1 
logarithms) and inhibits the contractile tone induced by carbachol in non-
sensitized airway (maximal effect reduced by ≃70%), compared with BNP-
untreated bronchi [8]. Intriguingly, in these experimental settings [8] the 
removal of epithelial cells from the bronchial lumen completely abolished the 
relaxant effects of BNP, suggesting that epithelium integrity is crucial for the 
modulatory role of BNP on the tone of human ASM.  
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Although in vitro studies carried out by using human isolated airways are 
useful to investigate the effect of drugs on airway tone, this experimental 
approach has certain limitations. For example, one cannot rule out the 
potential influence of cell types other than ASM in regulating bronchial tone.  
Indeed, in an attempt to identify the downstream mechanisms regarding the 
BNP-mediated relaxation of human ASM, the functional evidence obtained 
from in vitro experiments with isolated human bronchi have been 
supplemented by other types of in vitro laboratory studies using BEAS-2B 
cells and cultured human ASM cells [56]. Whilst BNP was unable to modulate 
per se the contractile response of asthmatic ASM cells, incubation with the 
supernatant from BEAS-2B cells pre-treated with BNP was effective in 
inhibiting the contractile response to histamine, reducing the contractile 
potency more than 1.5 logarithms [56]. Furthermore, the indirect relaxant 
effect of BNP in asthmatic ASM cells was comparable with that elicited by 
salbutamol [56].  
The pharmacological characterization of BNP in modulating the human ASM 
contractility is reported in Table 2.  
The relative activation of myosin light chain kinase (MLCK) and myosin light 
chain phosphatase (MLCP), a trimeric enzyme with a catalytic subunit called 
myosin phosphatase target subunit 1 (MYPT1) regulates ASM tone. The 
phorphorylation of MYPT1 makes MLCP inactive, resulting in a sustained 
myogenic tone [81]. Recently, it has been demonstrated that ASM cells, 
collected from asthmatic donors and incubated with the medium of BEAS-2B 
cells pre-treated with BNP, over-expressed the gene and protein levels of 
unphosphorylated and active form of MYPT1, whereas the phosphorylated 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 15 
and inactive pMYPT1Thr696 form was inhibited [56]. These findings provide an 
important piece of information concerning the functional antagonistic effect of 
BNP to protect against stimulation of ASM cells with histamine [8]. 
Since asthmatic ASM cells may directly alter their microenvironment by 
producing extracellular matrix proteins, pro-inflammatory mediators and 
adhesion receptors [82], further studies have been performed in human 
asthmatic ASM to elucidate the molecular and intracellular gene pathways 
involved in response to BNP challenge. Interestingly, although BNP indirectly 
modulated the activation of myosin light chain (MLC) by inhibiting the MLC 
phosphorylation (MLC-P) and the consequent interaction with actin, recent 
results have demonstrated that the BNP-induced relaxation of ASM did not 
depend upon immediate changes of expression of alpha-smooth muscle actin 
isoform (α-SMA). In fact, both immunofluorescence and western blotting 
analysis documented an analogous distribution and expression of α-SMA in 
asthmatic ASM cells incubated with the supernatant of BEAS-2B cells treated 
with BNP, compared with untreated cells [57]. On the other hand, the 
supernatant of BNP-treated BEAS-2B cells induced a rapid down-regulation of 
both calcium homeostasis-associated and epidermal growth factor receptor 
(EGFR) gene levels in asthmatic ASM cells [57]. 
 
8. The mechanism of action of BNP in human bronchi: from 
teleological activity to paradoxical effect 
The prevalent localization of NPR-A at the level of respiratory epithelium, and 
the absence of this receptor on ASM, suggests that the bronchoprotective role 
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elicited by BNP in both medium and small airways is indirect and potentially 
mediated by some autocrine mechanism. In addition, the results concerning 
the influence of BNP on the contractile tone of human ASM suggest that this 
NP may have a noteworthy teleological effect at the level of human respiratory 
system. Nevertheless, the specific mechanisms of action and the intimate 
pathways modulated by BNP via the activation of epithelial NPR-A have been 
only recently elucidated.   
As in the case of epithelium removal, the selective antagonism of M2 
muscarinic receptor by methoctramine and the selective inhibition of inducible 
nitric oxide synthase (iNOS) by aminoguanidine completely abolished the 
bronchoprotective effect of BNP in human isolated bronchi and asthmatic 
ASM cells [8, 56]. BNP indirectly enhanced the gene transcripts and the 
protein expression of iNOS in epithelium-intact bronchi and asthmatic ASM 
cells, but not in epithelium-denuded airways and human bronchial epithelial 
cells [8, 56]. In addition, inhibiting the vesicular release of endogenous 
acetylcholine from bronchial epithelial cells by quinine, an organic cation 
transporters (OCT) inhibitor [83, 84], also reduced the bronchoprotective 
effect of BNP in a concentration dependent manner [8].  
These evidences indicated that the integrity of bronchial epithelial cells, the 
activation of M2 muscarinic receptor and the activity of iNOS synthase are 
necessary conditions to allow the BNP-mediated effect on lung function.  
Further experiments demonstrated that BNP enhances the acetylcholine 
release from both epithelium-intact bronchi and BEAS-2B cells, but not from 
epithelium-denuded airways [8]. Therefore, we supposed that the 
acetylcholine itself, released from the respiratory non-neural cholinergic 
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system, might play a crucial role in the pathway that links the activation of 
epithelial NPR-A by BNP and the ASM relaxant response.  
This hypothesis has been confirmed by results obtained from experiments 
carried out by stimulating isolated bronchi and asthmatic ASM cells with very 
low concentrations of exogenous acetylcholine, in order to mimic the 
endogenous release of acetylcholine from non-neural cells [83, 84]. 
Paradoxically, we have evidenced that acetylcholine administered at pico-
nanomolar concentrations induced a modest but significant relaxation of both 
human isolated bronchi (≃30% vs. maximal relaxation induced by 
papaverine) and asthmatic ASM cells (≃20% vs. maximal relaxation induced 
by papaverine) pre-contracted by histamine whereas, as expected, at higher 
concentrations acetylcholine induced contractile response [83, 84]. Moreover, 
very low concentrations of acetylcholine enhanced the NO levels in both 
epithelium-intact and epithelium-denuded bronchi, an effect that was 
abolished by methoctramine and aminoguanidine [8]. The direct exposure of 
asthmatic ASM cells and BEAS-2B cells to BNP did not modulate the NO 
levels [8, 56], whereas the supernatant of BEAS-2B cells treated with BNP 
significantly increased the NO levels of asthmatic ASM cells, an effect that, 
also in this case, was abolished by methoctramine and aminoguanidine [56]. 
 
9. BNP: clinical considerations 
BNP and NT-proBNP are fast and sensitive biomarkers for diagnosing heart 
failure. In patients with COPD, the plasma concentrations of both BNP and 
NT-proBNP increase proportionally to the severity of right ventricular diastolic 
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dysfunction. For this reason we strongly suggest the addition of routine BNP 
testing in patients with a history of COPD increases the detection of newly 
diagnosed or previously unrecognized heart failure. Furthermore, BNP testing 
could represent advance in the management of patients with AECOPD 
because potentially it allows treatment monitoring. Interestingly, BNP levels 
can fall not only when patients are treated with diuretics, inotropes, and 
vasopressors. We documented that β2-agonists are able to induce a rapid 
reduction in BNP levels in patients admitted to emergency department for 
AECOPD [85]. It is not easy to explain why β2-agonists decrease BNP levels. 
The most plausible hypothesis is that they are able to influence the pulmonary 
hemodynamics. Alternatively, we can suggest that β2-agonists are able to 
cause an attenuation of air trapping, leading to a reduction of intrathoracic 
pressure, including pressure on the whole heart, and, consequently, to an 
improvement of right ventricular overload and left ventricular diastolic 
dysfunction. 
The big issue is that, in our opinion, BNP is not only a biomarker. The BNP 
Consensus Panel 2004 already highlighted that the rapidly evolving spectrum 
of therapeutic benefit and the emerging realm of additional therapeutic 
potential positions BNP as an increasingly important treatment option in the 
management of a growing number of cardiovascular conditions [86]. Our 
findings, which support a teleological role for elevated BNP concentrations, at 
least in patients with COPD in whom BNP might be part of a response aimed 
at mitigating the effects of the disease [87], suggest that this concept can also 
be applied to patients with COPD, in which BNP might be part of a response 
aimed at mitigating the effects of the disease. 
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In order to test this hypothesis it would be of interest to evaluate the effect of 
BNP administration in patients with COPD.  Nesiritide is the recombinant form 
of human BNP and has been tested in patients with acute heart failure and it 
is approved for the treatment of acute decompensated congestive heart 
failure although its use is not associated with a change in mortality or re-
hospitalizations. To date nesiritide has never been tested in patients with 
COPD in whom it may have, based on the above-mentioned assumptions, a 
beneficial effect on airway responsiveness. 
 
10. Conclusions 
The findings of recent studies carried out by our research group [8, 56-58] 
have permitted to clarify the pathway leading to the bronchorelaxant effect 
induced by BNP (Figure 1). 
BNP binds to NPR-A expressed at the level of airway epithelium with 
consequent vesicular release of very low concentrations of acetylcholine from 
bronchial epithelial cells, such as ciliated cells and neuroendocrine cells [8, 
83, 84]. Although there is less acetylcholine released from the airway 
epithelium compared with that from neurons [83, 84], it seems to be sufficient 
to activate prevalently postsynaptic M2 muscarinic receptors localized on the 
surface of surrounding ASM cells. The stimulation of M2 muscarinic receptor 
modulates the gene and protein expression of iNOS, that increases the NO 
levels in ASM and activates the NO/cGMP signaling. The NO/cGMP signaling 
is a proved pathway involved in the relaxation of ASM, which results in 
bronchodilation [88]. In fact the NO-mediated relaxation of ASM is controlled 
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by the activation of a soluble pool of GC that enhances the cGMP levels [56]. 
Thus, bronchial epithelium regulates the BNP-induced relaxant activity by an 
autocrine loop inducing the activation of the NO/cGMP pathway at the level of 
ASM. The NO/cGMP signaling stimulates specific protein kinases that, in turn, 
activate a number of targets such as MYPT1 [56]. MYPT1 fine tunes the 
MLCP activity with consequents ASM relaxation. In addition, the NO/cGMP 
pathway activated by BNP may prevent the BHR through a rapid modulation 
of calcium homeostasis and EGFR signaling in ASM, leading to the inhibition 
of MLCK activity [57, 89]. 
Concluding, the integrity of airway epithelium and its cooperation with ASM is 
crucial for the bronchorelaxant activity of BNP, suggesting for a teleological 
influence of this NP against the BHR and airway obstruction in asthma and 
COPD.  
 
11. Expert opinion 
BNP may represent an alternative therapeutic option for the treatment of 
chronic obstructive pulmonary disorders. The pharmacological rationale for 
administering BNP in asthmatic patients has been proved from bench to 
bedside [8, 56, 57, 78]. Furthermore, it has been suggested that BNP may 
also modulate the bronchial tone in COPD [8], since this NP prevented the 
cholinergic tone in human isolated airways. 
The bronchorelaxant activity of BNP is mediated by the interaction with the 
NPR-A localized at the level of bronchial epithelial cells. Therefore, the 
administration of BNP via inhalation is required to deliver this NP topically on 
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the airway epithelium. The inhalant administration of BNP should reduce the 
risk of hypotension, the main potential cardiovascular adverse event related 
with the systemic activation of NPR-A [56]. Epithelium integrity is an essential 
condition for the effectiveness of BNP but, unfortunately, it has been widely 
documented that asthmatic patients can present epithelium abnormalities and 
destruction at all levels of the airways [90, 91]. In addition, also COPD is 
associated with bronchial epithelial changes [92] that may potentially affect 
the BNP activity. These peculiarities suggest that BNP may have a role as a 
bronchodilator agent prevalently in stable and controlled patients, and that 
should be administered in combination with further bronchodilators in order to 
optimize the therapeutic approach [93].  
The density of vagal innervation is greatest in proximal airways and 
diminishes peripherally, being almost insignificant or absent at the level of 
bronchioles, at the least in human airways [94, 95]. BNP modulates the 
human bronchial tone independently from the interaction with the 
parasympathetic system, thus it may have a relevant influence as a 
bronchodilator agent at the level of small airways. Nevertheless, the relatively 
high molecular weight of BNP (3.7 kDa) [96], compared with that of the 
bronchodilators that are currently used in the clinical practice (overall <0.4 
kDa) [97], might imply technological difficulties in developing specific devices 
that are able to  deliver this NP up to small airways. 
In any case, BNP has the noteworthy characteristic to stimulate a physiologic 
autocrine loop at the level of bronchial wall, leading to bronchorelaxation and 
protection against BHR, representing a potential emerging drug for chronic 
obstructive pulmonary disorders [98]. Moreover, we cannot exclude potential 
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synergistic interaction of BNP when administered by inhalation in combination 
with low doses of further bronchodilators characterized by different 
mechanisms of action, such as long-acting β2 agonists (LABAs) and long-
acting muscarinic receptor antagonists (LAMAs). Finally, this combination 
approach may be of benefit in the treatment of chronic obstructive airway 
disorders by optimizing bronchodilation and preventing potential adverse 
events [60, 93, 99-103]. 
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Figure legend 
 
Figure 1. Autocrine loop and mechanism of action of BNP inducing human airways 
relaxation. BNP activates NPR-A expressed at the level of airway epithelium, with consequent 
vesicular release of very low concentrations of acetylcholine. Picomolar concentrations of 
acetylcholine activate prevalently postsynaptic M2 muscarinic receptors localized on 
surrounding ASM cells. The M2 muscarinic receptor stimulation modulates the iNOS activity, 
which in turn increases the NO levels and activates the intracellular NO/cGMP signaling. This 
pathway stimulates specific protein kinases that activate MYPT1 and MLCP, with consequent 
increase of MLC and ASM relaxation. The NO/cGMP pathway activated by BNP also 
prevents ASM contractility through a rapid modulation of calcium homeostasis, leading to the 
inhibition of MLCK activity and reduction of MLC-P. ACh: acetylcholine; ASM: airway smooth 
muscle; BNP: brain natriuretic peptide; Ca
++
: calcium; cGMP: cyclic guanosine 
monophosphate; iNOS: inducible nitric oxide synthase; MLC: myosin light chain; MLC-P: 
myosin light chain phosphorylation; MLCK: myosin light chain kinase; MLCP: myosin light 
chain phosphatase; MYPT1: myosin phosphatase target subunit 1; NO: nitric oxide; NPR-A: 
natriuretic peptide receptor A; pMYPT1: inactive (phosphorylated) myosin phosphatase target 
subunit 1. 
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Fig. 1 
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Tables 
Table 1. Influence of NPR-A activation on airways. 
Study NPR-A agonist Specie 
Experimental 
setting 
Functional effect 
Fernandes et al., 1992 [61] ANP 
Guinea 
pig 
In vitro 
Relaxation of tracheal smooth 
muscle 
Candenas et al., 1991 [65] ANP 
Guinea 
pig 
In vitro 
Relaxation of tracheal smooth 
muscle 
O'Donnell et al., 1985 [62] ANP Rat In vitro 
Relaxation of tracheal smooth 
muscle 
Ishii et al., 1989 [63] ANP Bovine In vitro 
Relaxation of tracheal smooth 
muscle 
Angus et al.,1994 [64] ANP Bovine In vitro 
Weak relaxation of bronchial 
smooth muscle 
Mizuguchi et al., 2000 [66] ANP 
Guinea 
pig 
In vivo 
Protection against propranolol-
induced bronchoconstriction after 
allergic reaction 
Candenas et al., 1991 [65] ANP Human In vitro 
No relaxation of bronchial smooth 
muscle 
Angus et al., 1994 [64] ANP Human In vitro 
Weak relaxation of bronchial 
smooth muscle 
Hulks et al., 1989 [71] ANP Human In vivo 
Bronchodilator response in 
asthmatic patients 
Chanez et al., 1990 [72] ANP Human In vivo 
Bronchodilator response in 
asthmatic patients 
Hulks et al., 1990 [67] ANP Human In vivo 
Reduction of airway resistance in 
normal subjects 
Hulks et al., 1991 [73] ANP Human In vivo 
Reduction of bronchial reactivity to 
inhaled histamine in asthmatic 
patients 
McAlpine et al., 1992 [74] ANP Human In vivo 
Reduction of bronchial reactivity to 
ultrasonically nebulized distilled 
water in asthmatic patients 
Angus et al., 1993 [69] ANP Human In vivo 
Bronchodilator response in 
asthmatic patients 
Angus et al., 1995 [70] ANP Human In vivo 
Reduction of bronchial reactivity to 
inhaled histamine 
Takagi et al., 1993 [76] BNP 
Guinea 
pig 
In vitro 
Relaxation of tracheal smooth 
muscle 
Ohbayashi et al., 1998 [75] BNP 
Guinea 
pig 
In vivo 
Prevention of ovalbumin-induced 
bronchoconstriction and 
microvascular leakage 
Akerman et al., 2006 [78] 
Nesiritide  
(human recombinant BNP) 
Human In vivo 
Bronchodilation in patients with 
asthma 
Edelson et al., 2012 [77] 
PL-3994  
(NPR-A agonist) 
Guinea 
pig 
In vivo 
Reduction in pulmonary inflation 
pressure 
Edelson et al., 2012 [77] 
PL-3994  
(NPR-A agonist) 
Human In vitro 
Relaxation of bronchial smooth 
muscle 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 33 
Table 2. Pharmacological characterization of BNP on the human airways contractility. 
   
Ex vivo COPD models  
(cholinergic stimulus) 
 
In vitro / ex vivo asthma models   
(histaminergic stimulus) 
Study Specimen Experimental setting 
Delta Emax 
(% cholinergic tone) 
Delta potency 
(pEC50) 
 
Delta Emax 
(% histaminergic tone) 
Delta potency 
(pEC50) 
Matera et al., 2009 [58]  Medium bronchi Effect on pre-contracted airways <-30% NC  -61% NC 
Matera et al., 2011 [8] Medium bronchi Effect on CRC to contractile agonists -71% -1.5  -33% -0.9 
Edelson et al., 2012 [77] Bronchioles Effect on pre-contracted airways -50% NC  NA NA 
Calzetta et al., 2014 [56] ASM cells Effect on CRC to contractile agonists NA NA  NC -1.6 
Calzetta et al., 2014 [56] ASM cells Effect on pre-contracted ASM cells NA NA  -50% NC 
ASM: airway smooth muscle 
CRC: concentration response curve 
Emax: maximal effect 
NA: data not available 
NC: data not calculable 
pEC50: negative logarithm of concentrations inducing 50% Emax 
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Highlights 
 
 BNP and NT-proBNP are fast and sensitive biomarkers for diagnosing 
heart failure 
 BNP testing in COPD patients increases the detection of chronic heart 
failure by about 20% 
 BNP and NT-proBNP levels may be elevated in patients with COPD 
without a history of heart failure  
 Ex vivo studies documented a BNP bronchorelaxant and 
bronchoprotective effect in human airways 
 BNP induces a physiologic autocrine loop at the level of bronchial wall 
and is a potential drug for COPD 
